developed a CAR T therapy called CT3.28H.BBζ for children with NB, which involves a new immunotherapy target called glypican-2(GPC2) which outperformed GD-2 CAR, K666.28H.BBζ, both in vivo and in vitro trials (130). Here, GPC2 is linked to neuroblastoma.